WuXi XDC Cayman Inc. is a Contract Research, Development and Manufacturing Organization (CRDMO) focused on the global antibody drug conjugate (ADC) and broader bioconjugate market. The company provides integrated, end-to-end services covering discovery, development, and cGMP manufacturing of drug substances and drug products. Its capabilities include bioconjugation process development, formulation and drug product development, GMP conjugation manufacturing, and the research, development, and manufacturing of chemical payloads and linkers. The company operates a single-source platform where all activities are conducted within a one-to-two-hour driving radius, facilitating streamlined project execution. WuXi XDC serves biopharmaceutical partners worldwide, supporting the development of therapies for patients. The company maintains manufacturing and R&D facilities in Wuxi, Shanghai, and Singapore, with the Singapore site achieving mechanical completion in 2025. It has developed proprietary technologies, including the WuXiDARx platform and WuXiTecan-1 and WuXiTecan-2 linker-payload technologies. In March 2026, the company became a controlling shareholder of BioDlink International Company Limited. The company was incorporated in December 2020 and is part of the WuXi Biologics group.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Drug Manufacturers - Specialty & Generic Homepage wuxixdc.com
Sector Healthcare IR page wuxixdc.com
Tags
antibody drug conjugates, bioconjugates, contract research development and manufacturing, payload-linker technology, gmp manufacturing, process development, formulation development, biologics, oncology, diagnostic reagents, WuXiDAR4, WuXiDARx, WuXiTecan-1, WuXiTecan-2, BioDlink International Company Limited, WuXi Biologics Conjugation Co. Ltd., WuXi Biologics
Press page —

Metrics

Valuation  
Market cap HK$ 80.38B
Market cap (USD) $ 10.244B
P/E 46.16
PEG 0.41
P/BV 5.89
P/S 9.83
P/OCF 28.83
P/FCF —
Dividend yield —
Turnover / mcap 0.46%
Returns  
ROE 17.1%
ROI 12.8%
ROIC 12.8%
Profit margin 24.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) 111.8%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 1.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 20.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022
Revenue 5.944B 4.052B 2.124B 990.423M
Net profit 1.48B 1.07B 283.538M 155.731M

Figure FY 2025 FY 2024 FY 2023 FY 2022
Share price 38.52 28.56 26.11 —
Price performance 12m 0.38 0.1 — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

News

Nov. 02, 2026

Share

linkedin sharing button

wechat sharing button

WuXi XDC’s Singapore Site Successfully Delivered First GMP Manufacturing of Drug Substance and Drug Product

Singapore, November 2, 2026 — WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that its Singapore site has successfully completed the first GMP manufacturing of bioconjugate drug substance (DS) and drug products (DP). This milestone marks WuXi XDC’s first overseas site’s official entry into substantial supply and delivery following GMP release, and validates the executability, consistent quality and delivery reliability of its end-to-end integrated manufacturing services in Singapore.

The first GMP batch of DS was manufactured in BCM3 facility DS line as a clinical resupply batch. BCM3 features an efficient and flexible “dual-function” design, offering integrated end-to-end commercial manufacturing services from antibody intermediates to conjugated drug substances. The production line supports batch sizes from 200 L to 2,000 L for antibody intermediates and up to 2,000 L for conjugated drug substances.

The first GMP batch of DP was manufactured in DP4 facility with a clinical batch size. Equipped with one 10 m² and two 30 m² lyophilizers, DP4 has an annual capacity of up to 8 million vials of liquid or lyophilized bioconjugates. TThe facility offers comprehensive end-to-end sterile drug product manufacturing and packaging services, covering tools washing and sterilization, compounding, vial washing, depyrogenation, filling, lyophilization, capping, external washing, manual visual inspection, automated visual inspection, labeling, and packaging.

Dr. Jimmy Li, CEO of WuXi XDC, stated: “The ADC industry faces rising demands for speed and agility in GMP supply. WuXi XDC’s ‘Global Dual-Sourcing’ strategy will provide clients with more agile and adaptable supply chain services. The successful completion of this first GMP manufacturing of DS and DP at our Singapore site proves that we have not only built manufacturing facilities aligned with international standards, but also established the capability to run consistent GMP operations and deliver reliably on client timelines. It validates the full closed loop of WuXi XDC’s overseas capacity — from GMP release to commercial supply. Clients’ trust in placing their GMP manufacturing at our Singapore site strongly endorses our integrated quality system and operational excellence. We will continue to foster seamless collaboration between the Singapore site and our sites in Wuxi, Shanghai, Hefei and Suzhou, delivering resilient, end-to-end CRDMO solutions for bioconjugate therapies to clients worldwide.”

About WuXi XDC

WuXi XDC Cayman Inc. (stock code: 2268.HK) is a globally recognized contract research, development, and manufacturing organization (CRDMO) specializing in bioconjugates. The company offers a wide range of innovative conjugation and payload-linker technologies to facilitate the development of next-generation antibody-drug conjugates (ADCs). Focused on early-stage research and development of ADCs and other bioconjugates, WuXi XDC offers comprehensive one-stop services from clinical to commercial manufacturing. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com

[Oct. 15, 2026

WuXi XDC Named the Winner of “Best CDMO” for the Fourth Consecutive Year and the Winner of "Best CRO" for the Second Consecutive Year](http://wuxixdc.com/wuxi-xdc-named-the-winner-of-best-cdmo-for-the-fourth-consecutive-year-and-the-winner-of-best-cro-for-the-second-consecutive-year/)

List

Notice:

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?

Yes, continue to proceed

No, stay on this Website

News

Sep. 22, 2026

Share

linkedin sharing button

wechat sharing button

WuXi XDC Celebrates GMP Release of Singapore Site, Ushering in a New Era of Global Expansion

WuXi XDC Celebrates GMP Release of Singapore Site, Ushering in a New Era of Global Expansion

September 21, 2026, Singapore – WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today held a grand GMP release ceremony for its Singapore manufacturing site at Tuas Biomedical Park. From announcing the new site in March 2024 to achieving GMP release of the BCM3 antibody intermediate and conjugated drug substance dual-function production line and the DP4 facility in August 2026, this important milestone was reached in only two and a half years. It marks the transition of WuXi XDC’s “Global Dual-Sourcing” strategy from blueprint to reality, opening a new chapter in empowering more global clients to accelerate commercial manufacturing.

  • Grand Ceremony Opens

At the beginning of the event, Dr. Jimmy Li, CEO of WuXi XDC, delivered opening remarks. He noted that the successful GMP release of the company’s first overseas manufacturing site is a key step in WuXi XDC’s global manufacturing footprint. Leveraging a globally leading quality system, cutting-edge innovation, and operational excellence, the company will continue to enhance the resilience and diversification of its supply system. The Singapore site will form a global collaborative network with sites in Wuxi, Shanghai, Hefei, and Suzhou, continuing to provide clients with end-to-end, one-stop CRDMO solutions for bioconjugates.

图片5

In her opening remarks at the event, Ms. Cindy Koh, Executive Vice President of the Singapore Economic Development Board (EDB) congratulated WuXi XDC for the GMP release of its Singapore site. She highlighted how the investment strengthens Singapore’s capabilities in manufacturing complex new modalities and reflects WuXi XDC’s confidence in Singapore as a trusted hub for biopharmaceutical manufacturing.

As a strategic partner of WuXi XDC, Mr. Li Daoquan, CEO of Morimatsu Pharmadule(China), was also invited to share his thoughts, recalling the efficient collaboration and outstanding execution between the two parties in the construction of the modular factory.

Following the speeches, the ribbon-cutting ceremony for the WuXi XDC Singapore site was held. Ms. Cindy Koh, Executive Vice President of EDB; Ms. Christine Wong, Assistant CEO (Cluster Group) of JTC Corporation; Dr. Jimmy Li, CEO of WuXi XDC; Mr. Jerry Zhang, COO of WuXi XDC; Dr. Marie Zhu, CTO of WuXi XDC; Dr. Hu Jun, Head of APAC Business Development & Global Commercial Operations and Singapore Site Management of WuXi XDC; and Dr. Zhang Xiao, Head of Conjugated Drug Substance and Singapore Site Production of WuXi XDC; Dr. JJ Luo, Head of Bioconjugate Drug Products Development of WuXi XDC, jointly took the stage, officially launching the GMP release of the WuXi XDC Singapore manufacturing site.

  • Capacity Upgrade to Empower Commercial Manufacturing

The Singapore site serves as a core cornerstone of WuXi XDC’s commercial manufacturing, spanning approximately 25,000 square meters. The site’s BCM3 dual-function production line and DP4 conjugated drug product facility have both successfully achieved GMP release.

  • The BCM3 features an efficient and flexible “dual-function” design, offering integrated end-to-end commercial manufacturing services from antibody intermediates to conjugated drug substances. The production line supports batch sizes from 200 L to 2,000 L for antibody intermediates and up to 2,000 L for conjugated drug substances. The line strictly follows international GMP standards such as FDA, EMA, and NMPA, and has established a comprehensive quality control system. In addition, the BCM4 facility is expected to achieve GMP release by the end of 2026, with a maximum single-batch capacity of up to 500 L of conjugated drug substance.

  • The DP4 facility is equipped with one 10 m² and two 30 m² lyophilizers, providing an annual production capacity of up to 8 million vials of liquid or lyophilized bioconjugates. The facility strictly adheres to GMP standards set by the FDA, EMA and HSA. The core filling line is equipped with a state‑of‑the‑art sterile isolator, enabling 100% in‑line filling weight checking. The filling speed can reach up to 300 vials per minute, with a camera‑based vision system that performs real‑time rejection of vials with missing or high‑seated stoppers. The facility offers comprehensive end-to-end sterile drug product manufacturing and packaging services, covering tools washing and sterilization, compounding, vial washing, depyrogenation, filling, lyophilization, capping, external washing, manual visual inspection, automated visual inspection, labeling, and packaging.

  • Site Tour Highlights One-Stop Capabilities

After the ceremony, WuXi XDC invited guests to tour the Singapore site. The tour attracted active participation from dozens of MNCs and global biotech companies. The site demonstrated to the industry its integrated end-to-end production capabilities for antibody intermediates, conjugated drug substances, and drug products. The tour covered key production areas of the Singapore site, including production lines, as well as the advanced quality control center and machinery area. Guests highly praised the site’s advanced modular design, internationally leading process equipment, and strict quality control system.

The successful GMP release of the WuXi XDC Singapore site is an important milestone in the company’s history and solid support for providing end-to-end, one-stop services to more clients worldwide. In the future, the Singapore site will deeply integrate and collaborate with multiple domestic sites to build an integrated, multi-dimensional comprehensive network, continuously empowering partners and the innovative development of the bioconjugate industry.

About WuXi XDC

WuXi XDC Cayman Inc. (stock code: 2268.HK) is a globally recognized contract research, development, and manufacturing organization (CRDMO) specializing in bioconjugates. The company offers a wide range of innovative conjugation and payload-linker technologies to facilitate the development of next-generation antibody-drug conjugates (ADCs). Focused on early-stage research and development of ADCs and other bioconjugates, WuXi XDC offers comprehensive one-stop services from clinical to commercial manufacturing. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com

[Sep. 17, 2026

WuXi XDC Out-Licenses WuXiTecan-2 Payload-Linker Technology Platform to Ona Therapeutics to Advance Novel ADC Research and Development](http://wuxixdc.com/wuxi-xdc-out-licenses-wuxitecan-2-payload-linker-technology-platform-to-ona-therapeutics-to-advance-novel-adc-research-and-development/)

List

Notice:

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?

Yes, continue to proceed

No, stay on this Website

News

Sep. 22, 2026

Share

linkedin sharing button

wechat sharing button

WuXi XDC Named the Winner of “Best CDMO” for the Fourth Consecutive Year and the Winner of “Best CRO” for the Second Consecutive Year

Shanghai, China, and San Diego, USA, October 15, 2026 – WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that it has been named the winner of “Best CDMO” at the 2026 World ADC Awards for the fourth consecutive year, along with the winner of “Best CRO” for the second consecutive year. WuXi XDC was the only CRDMO to claim both honors for two consecutive years in this year’s awards. These awards not only recognize the Company’s excellence in end-to-end, one-stop CRDMO services and innovative R&D capabilities, but also affirm its global leadership in the bioconjugate industry.

As one of the most influential annual awards in the global ADC sector, the World ADC Awards honor companies, teams and innovations that have made outstanding contributions to the field. This year’s World ADC Conference brought together global experts, scholars, and industry leaders to focus on the full lifecycle progress of ADCs and XDCs, from R&D stage to commercialization, as well as the latest breakthroughs in bioconjugates.

Dr. Jimmy Li, CEO of WuXi XDC, stated, “We are proud to have been named the winner of ‘Best CDMO’ for the fourth consecutive year and ‘Best CRO’ for the second consecutive year. We are also more aware than ever of the weight of this trust and thank our global clients and partners for their continued support. As the demand for bioconjugates becomes increasingly diverse, WuXi XDC will continue to be grounded in technological innovation, supported by global collaboration and high-quality delivery, and empower our clients to advance bioconjugates to clinical and commercial stages faster and more reliably, creating greater value for the industry and patients.”

As a leader in the bioconjugate CRDMO sector, WuXi XDC has earned industry recognition through its deep technical expertises, experience with complex processes, and one-stop services. By integrating cutting-edge technologies and global teams of industry experts, WuXi XDC ensures seamless multidisciplinary collaboration throughout the bioconjugates development process, minimizing risk and maximizing efficiency to keep projects moving forward smoothly and rapidly. The Company’s integrated ADC discovery services have successfully enabled clients to advance from DNA to preclinical candidate (PCC) within 10 months, from DNA to IND application within 15 months, and from late-stage development to BLA within 24 to 36 months.

In terms of R&D, WuXi XDC has built a technology portfolio spanning conjugation technologies (WuXiDARx™) and proprietary payload-linkers technologies (WuXiTecan-2™, X-LinC™, and WuXiLinker™). In February and August 2026, based on its WuXiTecan-2™ technology platform, the Company signed licensing agreements with Earendil Labs and Ona Therapeutics respectively, to collaborate on advancing three iCMC projects. To date, the Company has completed research on more than 22,000 ADC/XDC molecules and continues to explore cutting-edge areas such as bispecific ADCs, dual-payload ADCs, RDCs, DACs, AOCs, and APCs. In terms of global footprint, WuXi XDC has established a global network across Wuxi, Singapore, Shanghai, Suzhou, Hefei, and Jiangyin. In August 2026, the BCM3 dual-function production line and the DP4 facility at the Singapore site successfully achieved GMP release, marking the official launch of the Company’s first overseas manufacturing site.

According to WuXi XDC’s 2026 interim results, as of June 30, 2026, the Company had more than 810 global clients, and 15 of the top 20 pharmaceutical companies by revenue have chosen WuXi XDC as a partner. The Company has cumulatively enabled clients to submit more than 160 IND applications, with 328 iCMC projects, including 51 newly signed in the first half of 2026, a record high. The Company currently has more than 3,600 employees, over 50% of whom hold a master’s degree or higher. Leveraging a comprehensive talent development framework and dedicated talent programs, WuXi XDC continues to build high-caliber, globally minded talent pools.

About WuXi XDC

WuXi XDC Cayman Inc. (stock code: 2268.HK) is a globally recognized contract research, development, and manufacturing organization (CRDMO) specializing in bioconjugates. The company offers a wide range of innovative conjugation and payload-linker technologies to facilitate the development of next-generation antibody-drug conjugates (ADCs). Focused on early-stage research and development of ADCs and other bioconjugates, WuXi XDC offers comprehensive one-stop services from preclinical to commercial manufacturing. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com

WuXi XDC Contacts

Investor:[email protected]

Media:[email protected]

BD:[email protected]

[Sep. 17, 2026

WuXi XDC Out-Licenses WuXiTecan-2 Payload-Linker Technology Platform to Ona Therapeutics to Advance Novel ADC Research and Development](http://wuxixdc.com/wuxi-xdc-out-licenses-wuxitecan-2-payload-linker-technology-platform-to-ona-therapeutics-to-advance-novel-adc-research-and-development/)

List

Notice:

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?

Yes, continue to proceed

No, stay on this Website

Prompts

Wuxi XDC Cayman Inc. (ticker 2268), listed in Hong Kong.

ETFs Holding Wuxi XDC Cayman Inc.

ETF Weight in ETF Shares Market value As of
DFSE 0.04% 26,000 $ 238.965K Nov 12, 2026
AVSE 0.04% 10,500 $ 90.525K Nov 16, 2026
DFAE 0.03% 295,500 $ 2.716M Nov 12, 2026
DFEM 0.02% 176,500 $ 1.622M Nov 12, 2026
AVEM 0.01% 298,000 $ 2.569M Nov 16, 2026
DFAX 0.00% 64,500 $ 592.818K Nov 12, 2026